ProfileGDS5678 / 1444024_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 18% 16% 18% 19% 18% 18% 17% 18% 17% 19% 18% 19% 30% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4703618
GSM967853U87-EV human glioblastoma xenograft - Control 22.3917316
GSM967854U87-EV human glioblastoma xenograft - Control 32.4477718
GSM967855U87-EV human glioblastoma xenograft - Control 42.4077319
GSM967856U87-EV human glioblastoma xenograft - Control 52.3814118
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5042718
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4462517
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4267218
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3956417
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4424819
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4266818
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.424419
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6905930
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4403919